Gain Therapeutics Inc. (GANX) stock prices were up by 20.13% as of the market closing on September 8th 2021. This brought the price per share up to USD$9.49 at the end of the trading day. Subsequent premarket fluctuations saw the stock dip by 7.80%, bringing it down to USD$8.75.
GANX Stock’s Positive Topline Data
September 8th 2021 saw GANX stock announce the topline data from its clinical study of GT-02287 and GT-02329. The study is designed to evaluate the two lead Structurally Targeted Allosteric Regulators (STARs) compounds. These compounds are hoped to treat Gaucher and GBA 1 Parkinson’s Disease. The results indicated positive effects on all tested phenotypes. The biotechnology company is focused on identifying and optimizing allosteric binding sites that have never before been targeted in neurodegenerative diseases and lysosomal storage disorders.
Parkinson’s Disease Treatment
GANX stock’s lab is using human induced pluripotent stem cells to test the efficacy of the two lead STAR chaperones. These chaperones were developed by Gain Therapeutics and the stem cells were derived from patients with GD and GBA-associated Parkinson’s Disease. The studies in iPSC-derived cortical and dopaminergic neurons from neuronpathic Gaucher Disease patients demonstrate the potential of the compounds. This potential is in regard to an increase in the levels of GCase protein, its transport to the lysome, and its enzymatic activity. The two lead STAR chaperones have also been shown to decrease the levels of α-synuclein-p129 in dopaminergic neurons. This demonstrates the potential to treat GBA1-associated Parkinson’s Disease.
Scope of Topline Data
The data collected is highly promising, as it continues to consolidate the potential of GT-02287 and GT-02329. This development expands the collection of evidence that supports the company’s Site-Directed Enzyme Enhancement Therapy (SEE-Tx) drug discovery platform. The results of the study are being fully evaluated in the interest of presented a complete data set. This data set will be presented at the upcoming Michael J. Fox Foundation’s webinar. Furthermore, GANX stock anticipates initiating IND-enabling studies for Gaucher and Parkinson’s Disease in the fourth quarter of the current fiscal year.
Future Outlook for GANX Stock
GANX stock reported a promising quarter, consolidated by the success of its topline data for GT-02287 and GT-02329. The company is poised to capitalize on the opportunities presented to it as it spearheads the commercialization and proliferation of its treatments. Current and potential investors are hopeful that management will be able to usher in significant and sustained increases in shareholder value over the long term.
